Aegis Capital Starts Navidea Biopharmaceuticals (NAVB) at Hold

Article Related Articles (1) Stock Quotes (1) Comments (0)

Earlier, Aegis Capital initiates coverage on Navidea Biopharmaceuticals (NYSE: NAVB) with a Hold. PT $3.00.

NOTE: Burrill started at a Market Outperform today.

For an analyst ratings summary and ratings history on Navidea Biopharmaceuticals click here. For more ratings news on Navidea Biopharmaceuticals click here.

Shares of Navidea Biopharmaceuticals closed at $2.97 yesterday, with a 52 week range of $2.14-$4.77.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Navidea Biopharmaceuticals Announces the Presentation of Lymphoseek® Data at Joint International Oncology Congress (JIOC)
• Topeka Capital Starts CEVA Inc. (CEVA) at Buy
• Maxim Group Assumes Trina Solar (TSL) at Hold

Create E-mail Alert Related Categories

New Coverage

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?